Background Canagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia
as well as blood pressure, body weight, and albuminuria in people with diabetes. We …

Shah JP, Danoff JV, Desai MJ, Parikh S, Nakamura LY, Phillips TM, Gerber LH. Biochemicals
associated with pain and inflammation are elevated in sites near to and remote from active …

Context: Canagliflozin is a sodium glucose cotransporter 2 inhibitor developed to treat type 2
diabetes mellitus (T2DM). Objective: The purpose of this study was to describe the effects of …

Background: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that significantly
reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal …

Background: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the
risk of cardiovascular events. We report the effects on heart failure (HF) and cardiovascular …

Background Echinacea is a widely available over‐the‐counter herbal remedy. Tinctures of
echinacea have been shown to inhibit cytochrome P450 (CYP) in vitro. The effect of …

Sodium glucose co-transporter 2 inhibition is a novel mode of treatment for type 2 diabetes
mellitus (T2DM). The sodium glucose co-transporter 2 inhibitor canagliflozin lowered blood …

Sodium-glucose cotransporter 2 inhibition with canagliflozin decreases HbA1c, body weight,
BP, and albuminuria, implying that canagliflozin confers renoprotection. We determined …

OBJECTIVE This study assessed the incidence of serious adverse events of diabetic
ketoacidosis (DKA) among patients with type 2 diabetes treated with canagliflozin. RESEARCH …

Polymorphisms in the endothelial nitric oxide synthase (eNOS) gene have been associated
inconsistently with cardiovascular diseases. A maldistribution of eNOS variants among …